Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 1;28(10):1736-1741.
doi: 10.1016/j.bmcl.2018.04.036. Epub 2018 Apr 15.

Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne

Etienne Thoreau  1 , Jean-Marie Arlabosse  1 , Claire Bouix-Peter  2 , Sandrine Chambon  1 , Laurent Chantalat  1 , Sébastien Daver  1 , Laurence Dumais  1 , Gwenaëlle Duvert  1 , Angélique Feret  1 , Gilles Ouvry  1 , Jonathan Pascau  1 , Catherine Raffin  1 , Nicolas Rodeville  1 , Catherine Soulet  1 , Samuel Tabet  1 , Sandrine Talano  1 , Thibaud Portal  1
Affiliations

Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne

Etienne Thoreau et al. Bioorg Med Chem Lett. .

Abstract

Retinoids have a dominant role in topical acne therapy and to date, only RARβ and RARγ dual agonists have reached the market. Given the tissue distribution of RAR isoforms, it was hypothesized that developing RARγ -selective agonists could yield a new generation of topical acne treatments that would increase safety margins while maintaining the robust efficacy of previous drugs. Structural knowledge derived from the X-ray structure of known γ-selective CD437, suggested the design of a novel triaryl series of agonists which was optimized and ultimately led to the discovery of Trifarotene/CD5789.

Keywords: Acne; CD437; CD5789; RARγ; Trifarotene.

PubMed Disclaimer

LinkOut - more resources